1Church L1), McDermott MF. Canakinumab, a fully-human mAb a-gainst IL-lbeta for the potential treatment of inflammatory disorders [Jl. Curr Opin Mol Ther,2009,11( 1 ) : 81-89.
2Yokota S, Kikuchi M, Nozawa T, et al. An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab [ J ]. Nihon Rinsho Meneki Gakkai Kaishi,2012,35( 1 ) : 23-29.
3Kuemmerle-Deschner JB, Ramos E, Blank N,et al. Canakinumab ( ACZ885, a fully human IgG1 anti-IL-1 beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syn- drome (CAPS) [J]. Arthritis Res Ther,2011,13( 1 ) : R34.
4Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treat- ment of adults and children with cryopyrin-associated periodic syn- drome (CAPS) [J]. Biologics, 2010,4:131-138.
5Schlesinger N. Canakinumab in gout [ J ]. Expert Opin Biol Ther, 2012,12(9) : 1265-1275.
6Fabreguet I, So A. Canakinumab: a promising treatment in rheuma- tology[Jl. Re- Med Suisse, 2012,8(323) : 57-60.
7Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-inter- leukin-1 beta monoclonal antibody [ J 1. Clin Pharmacokinet,2012, 51 (6) : e1-18.
8Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacoki- netics and pharmacodynamics [ J]. Clin Pharmacol Ther, 2008,84 (5) :548-558.
9Kon6-Paut I, Lachmann H J, Kuemmerle-Deschner JB, et al. Sus- tained remission of symptoms and impro-ed health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled ran- domized withdrawal study [ J ]. Arthritis Res Ther, 2011 , 13 ( 6 ) : R202.
10Kuemmerle-Desehner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multieentre, phase II1 study e-aluating the safety and efficacy of canakinumab in patients with cryopyrin-associat- ed periodic syndrome across different se-erity phenotypes [ J]. Ann Rheum Dis,2011, 70(12): 2095-2102.
3Schumacher HR. The pathogenesis of gout [ J ]. Cleveland Clinic Journal of Medicine, 2008, 75 ( Suppl 5 ) : $2-$4.
4Dinarello CA. How Interleukin-1 fi induces gouty arthritis [ J ]. Ar- thritis Rheumatism, 2010, 62( 11 ) : 3140-3144.
5Ting JP, Lovering RC, Alnemri ES, et al. The NLR gene family: a standard nomenclature [ J ~. Immunity, 2008, 28 ( 3 ) : 285-287.
6Padwal MK, Sarma U, Saha B. Comprehensive logic based analyses of Toll-llke receptor 4 signal transduction pathway [ J ]. PLoS One, 2014,9(4) :e92481.
7Joosten LA, Netea MG, Mylona E, et al. Fatty acids engagement with TLR2 drive IL-1 ~ production via~ ASC-caspase-1 pathway by u- rate crystals in gouty arthritis[J]. Arthritis Rheum, 2010, 62 (ll) : 3237-3248.
8Holzinger D, Nippe N, Vogl T, et al. Myeioid-related proteins 8 and14 contribute to monosodium urate monohydrate crystal-induced in- flammation in gout [ J ]. Arthritis & Rheumatology, 2014, 66 ( 5 ) : 1327-1339.
9Kienhorst LBE, Lochem EV, Kievit W, et al. Gout is a chronic in- flammatory disease in which high levels of interleukin-8 ( CXCL8 ) , myeloid-related protein8/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovas- cular disease [ J ]. Arthritis rheumatology ,2015 ,67 (12) :3303-3313.
10Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodi- um mate crystals [ J ]. Journal of Clinical Investigation, 2006, 116 (8) : 2262-2271.
